Skip to main content

Timothy Williams

Equibles does not estimate personal net worth.

About Timothy Williams

Earlier roles on record: General Counsel at Vanda Pharmaceuticals Inc. (VNDA) until April 10, 2026. Vanda Pharmaceuticals Inc. reported in an 8-K filed April 2, 2026 that Timothy Williams resigned as Senior Vice President, General Counsel and Secretary, effective April 10, 2026. The proxy statement of Vanda Pharmaceuticals Inc. reports total compensation of $1,444,969 for Timothy Williams in fiscal 2025, including a base salary of $559,935. Disclosed compensation is on record for 8 fiscal years. Timothy Williams has spoken on 3 earnings calls across 1 company, most recently for Vanda Pharmaceuticals Inc. on May 3, 2023. The companies whose calls Timothy Williams spoke on are classified in the Healthcare sector.

“On March 29, 2026, Timothy Williams notified Vanda Pharmaceuticals Inc. (the "Company") of his resignation as the Company's Senior Vice President, General Counsel and Secretary, effective as of April 10, 2026, in order to pursue other endeavors.”
Vanda Pharmaceuticals Inc. Form 8-K, filed April 2, 2026 · Read the filing

Timothy Williams on recent calls

“I'll provide a brief recap of our ongoing litigation efforts, all of which are currently matters of public record, starting with our actions regarding HETLIOZ intellectual property and generic competition.”
General Counsel, Vanda Pharmaceuticals Inc. Q1 FY2023 Earnings Call ·
“As you probably know, in December, the Delaware District Court found certain of our HETLIOZ patent claims invalid or not infringed by the generic defendants in our Vanda litigation.”
General Counsel, Vanda Pharmaceuticals Inc. Q4 FY2022 Earnings Call ·
“As Mihales and Kevin both mentioned, we're continuing to address reimbursement delays and improper denials for HETLIOZ patients and we've made significant progress in the past quarter, particularly with state Medicaid programs.”
General Counsel, Vanda Pharmaceuticals Inc. Q4 FY2021 Earnings Call ·

Affiliation history

Company network

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Vanda Pharmaceuticals Inc. (VNDA) $559,935 $1,444,969
2024 Vanda Pharmaceuticals Inc. (VNDA) $541,000 $1,453,114
2023 Vanda Pharmaceuticals Inc. (VNDA) $520,000 $1,399,802
2022 Vanda Pharmaceuticals Inc. (VNDA) $466,400 $1,504,866
2021 Vanda Pharmaceuticals Inc. (VNDA) $440,000 $2,032,128
2020 Vanda Pharmaceuticals Inc. (VNDA) $400,000 $1,379,061
2019 Vanda Pharmaceuticals Inc. (VNDA) $379,315 $2,022,854
2018 Vanda Pharmaceuticals Inc. (VNDA) $144,886 $2,002,856

Recent activity